Skip to main content

Cannalysis raised $22M to test cannabis products for Vitamin E, but can they close this conversation once and for all?

With billions of dollars pouring into the cannabis industry and the market positioned to grow over 3x by 2022, the emergence of new companies in the space has been ubiquitous. Though this growth has no stopping point in sight, given the ever increasing acceptance of marijuana use nationwide, mainstream media headlines about the perils of “vaping” are making some customers more cautious about their ingestion of the substance.

While many think companies like Juul Labs, creator of the nicotine salt based Juul e-cigarette, are the main problem, a deeper look into the stories of hospitalizations and vape related lung diseases shows that the main problem is the presence and inhalation of Vitamin E acetate oil — a chemical predominantly found in off-brand cannabis vape pens, not necessarily their nicotine based counterparts. This outbreak of vape related lung diseases prompts the need for better testing of products before they hit the shelves, and that is just what the Santa Ana based company Cannalysis seeks to do.

Cannalysis recently raised $22.6M to bring a new testing process for cannabis vape additives to market, their main focus being to test for Vitamin E acetate. The fundraising round was led by CanLab, the largest cannabis testing company in the United States, whose investment was predicated on Cannalysis’ use of robotics and machine learning to speed up their testing process and make it increasingly accurate. Founder and CEO Brian Lannon explains his rationale for building the company, saying: 

“The big story that’s been going out over the last week isn’t the product that’s going out in cannabis, but an additive called Vitamin E acetate. We have developed a test for that… As part of the different compliance testing that’s required, it’s not mandated to test for any of these additives… What I’m anticipating based on the phone calls we’ve been getting is that a lot of our customers want to get the test to show that they’re not using the stuff.”

As a Business to Business (B2B) company, Cannalysis tests products for other cannabis companies. They track a company’s products through their supply chains and offer data management services to them as well. In addition, Cannalysis has integrated their services with WeedMaps, a centralized database of cannabis dispensaries and products, so end buyers can verify not only the strength of the product they’re buying, but also whether or not there are any additives of which they should be aware. With public worries over vaporizing cannabis products, Cannalysis’ incorporation (and this new investment) comes at a perfect time. I’ll be interested to see what effects this company has on the broader cannabis industry landscape, as well as if they can close the curtain on this discussion of harmful vape additives.

Comments

Post a Comment

Popular posts from this blog

AB5 — A Benefit or A Cost?

On September 18th, 2019, California Governor Gavin Newsom signed into law Assembly Bill 5 (AB5) – “arguably the strongest of its kind in the nation,” according to the LA Times . What exactly is this, you may ask? Well, AB5 is a piece of legislation which, “will help reduce worker misclassification – workers being wrongly classified as ‘independent contractors’ rather than employees, which erodes basic worker protections like the minimum wage, paid sick days and health insurance benefits,” says Newsom . Although this sounds all well and good, “gig economy” companies such as Uber, Lyft, Postmates, and the like – companies that take advantage of app-based technology to allow individuals to work on their own time for extra cash – will likely feel the pain of increased regulation on components of their core business models. Threats may arise for these companies, ultimately putting into question the longevity of their businesses. Since these companies identify their workers as independe...
Post a Comment
Read more

Op-Ed: Decriminalize Psychedelics

In June of this year, the world’s first venture capital firm focused on psychedelics was established in Canada. Three months later, the firm, Field Trip Ventures, partnered with the University of the West Indies to create the first ever legal research and cultivation facility for psilocybin (the active compound in “magic mushrooms”) in Kingston, Jamaica. Some say a so-called “psychedelic renaissance” is upon us, as research into the psychotherapeutic benefits of psychedelic substances like LSD and Psilocybin has seen a resurgence. But with these drugs still classified as Schedule I in the United States, we need drastic societal changes if we want to see any tangible evidence-based results. Just because something is illegal does not mean it’s wrong. In fact, just because many people believe something is wrong doesn’t mean it's wrong. Since the Controlled Substances Act was passed in 1970 during Richard Nixon’s presidency, the general public has perceived psychedelic drugs (the class...
Post a Comment
Read more

PayPal To Acquire LA-Based Startup Honey

A few days ago , payment processing platform PayPal (say that five times fast…) announced they would be acquiring Honey, a Google Chrome extension used for finding discounts while shopping online. While most headlines boast about the numerical value of the acquisition — a whopping $4B — I’m more interested in the reasoning for the company purchase. Honey is an LA-based startup focusing on making the online shopping experience better for the consumer. You can download their service as a Google Chrome extension, and then it automatically gets put to use when surfing the web. When you go on Amazon for example and pull up a product’s webpage, Honey will automatically search the web for better deals on the same item — easy as that. President and CEO of PayPal Dan Schulman says , “Honey is amongst the most transformative acquisitions in PayPal's history. It provides a broad portfolio of services to simplify the consumer shopping experience, while at the same time making it more affor...
Post a Comment
Read more